LeonaBio, Inc. SEC filings document the company’s status as a Delaware clinical-stage biopharmaceutical issuer listed on The Nasdaq Capital Market under the LONA ticker. Its 8-K reports furnish financial results, business updates, Regulation FD disclosures, board matters, and material events tied to its product candidates and corporate development activity.
Registration statement amendments cover delayed or continuous securities offerings, while amended material-event filings document the completed Sermonix license transaction, related securities issuance, and SEC accounting disclosures under Regulation S-X. The filing record also reflects the company’s transition from Athira Pharma to LeonaBio and the capital-structure disclosures associated with its common stock and warrants.
LeonaBio, Inc. director James A. Johnson received a grant of stock options as part of his outside director compensation. He was awarded 28,000 stock options to acquire LeonaBio common stock at an exercise price of $8.35 per share. The options vest on the earlier of June 23, 2027, or the day immediately before the next annual stockholder meeting that occurs after June 22, 2026, and expire on June 22, 2036. Following this grant, Johnson holds 28,000 options to purchase LeonaBio common stock directly.
LeonaBio, Inc. director Barbara Kosacz received a grant of stock options as part of outside director compensation. The award covers 28,000 stock options for common stock with an exercise price of $8.35 per share, expiring on June 22, 2036.
The options will vest on the earlier of June 23, 2027, or the day immediately before the next annual stockholder meeting that occurs after June 22, 2026. Following this grant, she holds 28,000 derivative securities directly.
LeonaBio director Grant Pickering received a grant of stock options for 28,000 shares of common stock. The options have an exercise price of $8.35 per share and expire on June 22, 2036. All 28,000 options were outstanding after the transaction, held as a direct position.
The options will vest on the earlier of June 23, 2027 or the day immediately before the next annual stockholder meeting that occurs after June 22, 2026. The grant was made under LeonaBio’s Outside Director Compensation Policy, indicating it is part of routine director compensation rather than an open-market purchase.
LeonaBio, Inc. reported the results of its 2026 Annual Meeting of Stockholders. Of 9,393,514 common shares outstanding as of May 1, 2026, 7,908,604 shares were present or represented by proxy, representing approximately 84.19% of shares entitled to vote, which was enough to conduct business.
Stockholders elected three Class III directors—Kelly A. Romano, James A. Johnson and Natalie Holles—to terms running until the 2029 annual meeting, with strong majorities of votes cast in favor. They also ratified the appointment of Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026.
In advisory votes, stockholders approved the compensation of LeonaBio’s named executive officers and indicated a preference to hold future advisory votes on executive pay every three years. The company and its board plan to follow a three-year frequency until the next required vote on this question.
LeonaBio, Inc. Schedule 13G reports that ADAR1 Capital Management, LLC and Daniel Schneeberger beneficially own 727,481 shares of common stock, representing 7.7% of the 9,393,514 shares outstanding as of March 31, 2026. The filing states these holdings include 568,234 shares held by ADAR1 Partners, LP, 77,371 shares held by Spearhead Insurance Solutions IDF, LLC and 81,876 shares held by separately managed accounts.
The filing also notes 1,230,315 shares underlying common warrants are excluded from the reported beneficial ownership because their exercise or exchange is subject to a 4.99% beneficial ownership limitation. ADAR1 Capital Management is disclosed as the investment manager/sub-advisor and Mr. Schneeberger is reported as a control person for the same holdings.
LeonaBio, Inc. is asking stockholders to vote at its 2026 virtual annual meeting on June 22, 2026 at 8:00 a.m. Pacific Time. Holders of 9,393,514 shares of common stock outstanding as of May 1, 2026 may vote online, by phone, mail, or during the webcast.
Stockholders will elect three Class III directors (Kelly A. Romano, James A. Johnson and Natalie C. Holles), ratify Ernst & Young LLP as independent auditor for 2026, approve on an advisory basis executive compensation, and choose how often future advisory pay votes occur. The board recommends voting FOR all proposals and selecting a THREE-YEAR frequency for Say‑on‑Pay votes.
LeonaBio, Inc. director Natalie C. Holles received a grant of stock options covering 56,000 shares of common stock. The options have an exercise price of $9.63 per share and expire on May 4, 2036. The award vests in equal monthly installments over 36 months, contingent on her continued service as a Service Provider under the company’s 2026 Equity Incentive Plan. Following this grant, she holds 56,000 stock options directly.
LeonaBio, Inc. director Peter B. Silverman received a grant of stock options covering 56,000 shares of common stock. The options have an exercise price of $9.63 per share and expire on May 4, 2036. They vest monthly over 36 months, contingent on his continued service to the company.
Following this grant, Silverman holds 56,000 stock options directly, reflecting a compensation award rather than an open-market share purchase or sale.
LeonaBio, Inc. director Callori Fred received a grant of stock options covering 56,000 shares of common stock. The options have an exercise price of $9.63 per share and expire on May 4, 2036. All 56,000 options are held directly after this award.
The options are scheduled to vest in equal installments monthly over 36 months from the grant date, as long as the director continues to serve as a service provider under LeonaBio’s 2026 Equity Incentive Plan.